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Rapport de synthèse 
La résistance à l'insuline chez les souris déficientes en synthase neuronale de monoxyde 
d'azote est due à un mécanisme alpha-adrénergique 
Le monoxyde d'azote (NO) joue un rôle important dans la régulation de l'homéostasie du 
système cardiovasculaire et du glucose. Les souris déficientes pour le gène codant !'isoforme 
neuronale de la synthase de monoxyde d'azote (nNOS) sont résistantes à l'insuline, mais les 
mécanismes sous-jacents sont inconnus. Le manque de NO produit par la nNOS pourrait être 
à l'origine d'une diminution de la perfusion du muscle squelettique et ainsi d'une diminution 
de l'apport de substrat. Alternativement, le déficit de nNOS normalement hautement exprimé 
dans le tissu musculaire squelettique pourrait directement y perturber la consommation de 
glucose. Finalement l'absence de l'action sympatholytique du NO neuronal pourrait diminuer 
la sensibilité à l'insuline. 
Afin de tester ces hypothèses nous avons étudié, chez des souris déficientes en nNOS et des 
souris-contrôle, la consommation corporelle totale de glucose et le flux musculaire 
squelettique pendant des clamps hyperinsulinémiques euglycémiques in vivo, ainsi que la 
consommation de glucose dans le muscle squelettique in vitro. De plus nous avons analysé les 
effets d'une inhibition alpha-adrénergique sur la consommation de glucose pendant les 
clamps hyperinsulinémiques euglycémiques in vivo. Le taux de perfusion de glucose pendant 
les clamps était grossièrement 15 pourcent plus bas (P<0.001) chez les souris déficientes en 
nNOS que chez les souris-contrôle. Cette résistance à l'insuline chez les souris déficientes en 
nNOS n'était due ni à une stimulation déficiente du flux sanguin musculaire par l'insuline ni à 
un défaut intrinsèque de la consommation de glucose du muscle (qui étaient comparables dans 
les deux groupes), mais à un mécanisme alpha-adrénergique, car l'administration de 
phentolamine rétablissait la sensibilité à l'insuline chez les souris déficientes en nNOS. 
Ces résultats suggèrent qu'une hyperactivité sympathique, potentiellement due à la perte de 
l'inhibition neuronale centrale du flux sympathique par le NO provenant de nNOS, contribue 
à la résistance à l'insuline des souris déficientes en nNOS. Par ailleurs ces résultats tendent à 
prouver qu'un défaut de production de NO provoquerait une résistance à l'insuline par des 
mécanismes différents selon !'isoforme de NO synthase déficiente (par exemple chez les 
souris déficientes pour la forme endothéliale de NO synthase, il a été montré que la résistance 
à l'insuline est due à un défaut de stimulation de la perfusion musculaire par l'insuline et à un 
défaut du signalling de l'insuline dans la cellule musculaire squelettique). 
Chez l'être humain il est établi que les états de résistance à l'insuline sont associés à une 
synthèse défectueuse et/ou une mauvaise biodisponibilité du NO, ainsi qu'à une hyperactivité 
sympathique. Nous spéculons que la perte d'inhibition centrale du flux sympathique 
représente un mécanisme contribuant à la résistance à l'insuline et ses complications 
cardiovasculaires chez l'être humain. 
Peer reviewed article 
1 C.S and U.S. 
contributed 
equally to this 
work. 
This work was 
supported by 
grants from the 
Swiss National 
Science Founda-
tion, the Fondation 
Romande pour la 
Recherche sur le 
Diabète, the Cloëtta 
Foundation, the 
Emma Muschamp 
Foundation, the 
CardioMet Founda-
tion and the Placide 
Nicod Foundation. 
Insulin resistance in mice lacking 
neuronal nitric oxide synthase is related 
to an alpha-adrenergic mechanism 
P. Turini0 , S. Thalmann°, P.-Y. Jayet 0 , S. Cook 0 , C. Mathieu0 , R. Burcelinb, P. Nicod0 , P. Vollenweider 0 , 
C. Sartori 0.1, U. Scherrer 0 •1 
• Department oflnternal Medicine and Botnar Center for Clinical Research, CHUV, Lausanne, 
Switzerland 
h CHU Rangueil, Toulouse, France 
Summary 
Background: nitric oxide (NO) plays an impor-
tant role in the regulation of cardiovascular and 
glucose homeostasis. Mice lacking the gene en-
coding the neuronal isoform of nitric oxide syn-
thase (nNOS) are insulin-resistant, but the under-
lying mechanism is unknown. nNOS is expressed 
in skeletal muscle tissue where it may regulate 
glucose uptake. Alternatively, nNOS driven NO 
synthesis may facilitate skeletal muscle perfusion 
and substrate delivery. Finally, nNOS dependent 
NO in the central nervous system may facilitate 
glucose disposa! by decreasing sympathetic nerve 
activity. 
Methods: in nNOS null and control mice, we 
studied whole body glucose uptake and skeletal 
muscle blood flow during hyperinsulinaemic 
clamp studies jn vivo and glucose uptake in skele-
tal muscle preparations in vitro. We also exam-
ined the effects of alpha-adrenergic blockade 
(phentolamine) on glucose uptake during the 
clamp studies. 
Introduction 
Metabolic insulin resistance is a problem of 
major clinical importance. Epidemiological ob-
servations demonstrate an association between in-
sulin resistance and cardiovascular disease [1---4], 
but the mechanism relating these disorders is not 
known. Nitric oxide (NO) plays an important role 
in the regulation of metabolic and cardiovascular 
homeostasis in experimental animal models and 
humans. In humans, altered NO synthesis and/or 
bioavailability is associated with cardiovascular 
disease [5-8] and insulin resistance [7, 9], and may 
represent a link between these two disease states. 
Studies in mice indicate that each of the three ni-
tric oxide synthase (NOS) isoforms play a role in 
Results: as expected, the glucose infusion rate 
during clamping was roughly 15 percent lower in 
nNOS null than in control mice (89 (17) vs 101 
(12) [-22 to -2]). Insulin stimulation of muscle 
blood flow in vivo, and intrinsic muscle glucose 
uptake in vitro, were comparable in the two 
groups. Phentolamine, which had no effect in the 
wild-type mice, normalised the insulin sensitivity 
in the mice lacking the nNOS gene. 
Conclusions: insulin resistance in nNOS null 
mice was not related to defective insulin stimula-
tion of skeletal muscle perfusion and substrate de-
livery or insulin signaling in the skeletal muscle 
cell, but to a sympathetic alpha-adrenergic mech-
amsm. 
Key words: nitric oxide; neuronal nitric oxide syn-
thase; insulin resistance; sympathetic nerve activity; 
muscle blood fiow; intriusic muscle glucose uptake 
the regulation of glucose homeostasis. Endothe-
lial nitric oxide synthase (eNOS) null mice are 
hypertensive and insulin resistant [10, 11]. The 
latter appears to be caused by impaired insulin 
stimulation of blood flow and substrate delivery 
to skeletal muscle tissue, mitochondrial dysfunction 
[12, 13] and an intrinsic defect of muscle glucose 
uptake [11]. Partial deletion of the eNOS gene 
(eNOS+/-) predisposes to exaggerated high-fat-
diet-induced arterial hypertension and insulin re-
sistance in mice, demonstrating an important 
interaction between environmental and genetic 
factors in the regulation of cardiovascular and 
glucose homeostasis [14]. iNOS null mice do not 
Figure 1 
Glucose infusion 
rates during euglyc-
aemic hyperinsulin-
aemic clamp studies 
in control (squares) 
and in nNOS null 
(circles) mice in the 
absence (filled sym-
bols; n = 18 control 
and 16 nNOS null 
mice) and the pres-
ence (open symbols; 
n = 5 control and 
13 nNOS null mice) 
of alpha-adrenergic 
blockade. Data are 
the mean with bars 
showing the standard 
error of the mean 
(P <0.001, for group 
and lime effects as 
Weil as for their inter-
action: ANOVA be-
tween nNOS null 
Without phento-
lamine and both 
nNOS null mice with 
Phentolamine and 
wild type mice). 
develop high-fat-diet-induced insulin resistance, 
indicating that iNOS-driven NO synthesis con-
tributes to insulin resistance in this model [15]. 
Neuronal NOS (nNOS) dependent NO also 
appears to play a role in the regulation of insulin 
sensitivity, since nNOS null mice are insulin re-
sistant [16], but the underlying mechanisms are 
unknown. nNOS could modulate insulin sensitiv-
ity in several ways. It is highly expressed in skele-
tal muscle tissue [17], where it may facilitate glu-
cose uptake. Alternatively, nNOS derived NO 
could modulate insulin sensitivity by regulating 
skeletal muscle perfusion and substrate delivery, 
which are NO dependent [18, 19]. Finally, nNOS 
derived NO inhibits central [20-22] neural sym-
pathetic outflow and counteracts sympathetic vas-
Methods 
All protocols were approved by tbe Institutional An-
imal Care and Use Committee. 
nNOS null C57BL6 mice, generated as previously 
described [16], were used. nNOS null and contrai mice 
were generated by mating heterozygous animais from our 
colony. Ten to 14 week old male and female mice of gen-
eration 9 to 12 were used for tbe studies. 
Hyperinsulinaemic euglycaemic clamp studies 
Euglycaemic hyperinsulinaemic clamps in freely 
moving mice were performed as described previously 
[11]. 16 nNOS null and 18 contrai mice were studied. 
Briefly, on the day of the clamp, after a 6-hour fast, insulin 
was infused (18 mU/kg per min, a dose known to suppress 
hepatic glucose production) [11, 14] into tbe femoral vein 
for 150 minutes. Throughout tbe clamp, blood samples 
were collected every 5 minutes from tbe tip of tbe tail to 
determine tbe blood glucose concentration. Euglycaemia 
(5.5 (SD 0.5) mmol/L) was maintained by periodic ad-
justment of a variable infusion of 15% glucose. The 
steady state glucose infusion rate was calculated as tbe 
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cular and metabolic effects in skeletal muscle 
tissue [2 3-2 5]. Sympathetic overactivity is as-
sociated with insulin resistance in animals and 
humans [2, 9]. Thus, nNOS derived NO could 
exert beneficial effects on insulin sensitivity by de-
creasing sympathetic activity. 
To test these hypotheses, we measured, in 
nNOS null and control mice, insulin stimulated 
whole body glucose uptake and skeletal muscle 
blood flow during euglycaemic hyperinsulinaemic 
clamp studies in vivo, and basal and insulin stimu-
lated glucose uptake in isolated skeletal muscle 
preparations in vitro. We also tested the effects of 
alpha-adrenergic blockade on whole body glucose 
uptake during clamp studies in these two groups 
of animals. 
mean of tbe values obtained every 5 minutes during tbe 
last 30 minutes of tbe clamp. 
Identical studies were performed in 13 knockout and 
5 contrai mice following tbe intraperitoneal injection of 
phentolamine (20 mg/kg, a dose known to prevent tbe in-
crease in arterial blood pressure evoked by tbe a-ad-
renergic agonist phenylephrine) [26] 20 minutes before 
starting the clamp. 
Muscle blood flow 
Insulin stimulation of muscle blood flow was meas-
ured in anestbetized mice (4 nNOS null, 7 control mice) 
during a 90-minute glucose clamp witb a laser Doppler 
probe (Perimed, Periflux System 5000, Probe #403, 
Sweden) inserted into tbe hindlimb skeletal musculature 
as described previously [11]. The body temperature was 
maintained at 37.5 ± 0.5 °C witb a temperature control 
unit (Frederick Haer and Co., Bowdoinham, ME). The 
blood flow signal was recorded on a persona! computer 
using specific data acquisition software (Powerlab 400, 
AD). 
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Figure 2 
lnsulin stimulation of 
muscle blood flow at 
the end of a 90-min-
ute hyperinsulin-
aemic euglycaemic 
clamp in 4 nNOS null 
and 7 contrai mice. 
Horizontal lines rep-
resent means. 
Figure 3 
Basal and insulin 
stimulated 2-deoxy-
glucose uptake in 
soleus and EDL mus-
cle of nNOS null 
(filled symbols) and 
contrai (open sym-
bols) mice. Soleus 
muscles of 8 knock-
out and 4 contrai 
mice and EDL mus-
cles of 4 knockout 
and 6 contrai mice 
were studied. 95% 
confidence interval 
for the difference be-
tween graup means: 
[-0.01 to 0.07] (basal) 
and [-0.12 to 0.09] 
(insulin) for the 
soleus muscle. [-0.07 
to 0.04] (basal) and 
[-0.04 to 0.09] (insu-
lin) for the EDL mus-
cle, Horizontal lines 
represent means. 
Glucose utilisation in isolated skeletal muscle 
After cervical dislocation, the soleus and EDL mus-
cles were rapidly isolated, tied separately to silk threads 
by the tendons and immersed for 20 minutes in an incu-
bation medium (Krebs-Ringer bicarbonate [pH 7.35] 
supplemented with 0.1 % bovine serum albumin [Frac-
tion V, pH 7.0] and 2 mM sodium pyruvate) [11]. Under 
an atmosphere containing 5% C02 and 95% 02, the mus-
cles were then incubated for an additional 60 minutes at 
3 7 °C in this medium, in the presence or absence of 20 nM 
insulin. Thereafter, the muscles were immersed for 
20 minutes in the incubation medium supplemented with 
3H-2-deoxyglucose (0.1 mM, 1 µCi/ml). During this im-
mersion the 3H-2-deoxyglucose is metabolised to 3H-2-
deoxyglucose-6-phosphate. To stop the reaction, the 
muscles were immersed in ice-cold saline buffer, washed 
for 30 minutes and then dissolved in NaOH lM at 60 °C 
for 60 minutes. An aliquot of the extract was spun clown 
and the 3H-labeled radioactivity was counted in the pres-
ence of a scintillation buffer. Sample aliquots were used 
for protein determination. Soleus muscles of 8 nNOS 
null and 4 contrai mice, and EDL muscles of 4 nNOS 
null and 6 contrai mice, were studied. 
Measurement of arterial blood pressure 
Blood pressure was measured in awake, partially re-
stricted mice (10 nNOS null and 6 contrai mice) with 
fluid filled PE-10 tubing connected to a pressure trans-
Results 
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ducer, as described previously [11]. Blood pressure values 
were averaged over a 20 minute period. 
Analytical methods 
Fasting blood glucose and insulin (ELISA, Mer-
codia, Uppsala, Sweden) plasma concentrations were 
measured in conscious mice (n :2:9 for each graup) after 
a 5-hour fast. Free fatty acids (n :2:8 for each graup) 
were measured after a 5-hour fast by colorimetric enzy-
matic determination (NEFA-C, Wako). 
Statistical analysis 
Data were analysed with the JMP software package 
(SAS Institute Inc., Gary, North Caralina, USA), using 
the confidence interval for difference between means for 
single comparisons. Data are presented as mean (standard 
deviation) and compared using a 95% confidence interval 
for the difference between graup means [95% confidence 
interval]. For the comparison of the glucose infusion 
rates during euglycaemic hyperinsulinaemic clamp stud-
ies (figure 1) we used a two-way analysis of variance 
(ANOVA) for repeated measures on one way (time) for 
assessing solution and time effects, as well as their inter-
action. Bonferrani correction was used to avoid bias due 
to multiple comparisons. Symmetrical distribution of ail 
the data was confirmed using the Shapira-Wilk test for 
normality. 
Body weight (20.9 (2.9) vs 20.9 (1.9) g), fast-
ing plasma glucose (5 .6 (0.4) vs 5 .5 (0.4) mmol/L), 
insulin (16 (8) vs 18 (7) µU/ml), and free fatty acid 
concentration (1.0 (0.3) and 0.9 (0.3) mmol/L) 
were comparable in nNOS null and control mice. 
As expected, the nNOS null mice were insulin 
resistant (figure 1), as evidenced by a roughly 
15 percent lower glucose infusion rate during the 
last 30 minutes of the clamp (89 (17) vs 101 (12) 
[-22 to -2]. During the clamp studies, the glucose 
(5 .6 (0.4) vs 5 .5 (0.4) mmol/L) and insulin plasma 
concentration (340 (120) vs 320 (50) µU/ml) were 
comparable in nNOS null and control mice. 
To determine whether insulin resistance in 
the nNOS-/- mice was related to a defect in in-
sulin stimulation of skeletal muscle perfusion, 
which is NO dependent,[18] we measured skele-
tal muscle blood flow during clamp studies. We 
found that the increase in muscle blood flow at 
the end of the clamp was comparable in the 
nNOS null and the control mice (37 (14) vs 43 
(19) [-29 to 16]) % (figure 2). Mean arterial blood 
pressure (109 (5) vs 107 (13) [-8 to 11] mm Hg) 
was also comparable in the nNOS null and con-
trol mice. 
nNOS is highly expressed in skeletal muscle 
tissue. To test whether nNOS deficiency may im-
pair skeletal muscle glucose uptake, we measured 
glucose uptake in isolated soleus and EDL muscle 
in vitro. The basal and insulin stimulated muscle 
deoxyglucose uptake were comparable in the 
nNOS null and the control mice (figure 3). 
Loss of nNOS-dependent NO may result in 
increased central neural sympathetic outflow that 
could induce insulin resistance. Therefore, we ex-
amined the effects of alpha-adrenergic blockade 
on insulin-stimulated glucose uptake during 
clamp studies. Phentolamine significantly in-
creased the glucose infusion rate in the nNOS 
null mice (from 89 (17) to 102 (14) [1 to 25] 
Discussion 
Over the past decade, evidence has accumu-
lated indicating that nitric oxide generated by 
each of the three NOS isoforms plays an impor-
tant role in the regulation of glucose homeostasis, 
but it is not known, whether this regulation in-
volves isoform-specific mechanisms or not. Here 
we found that insulin resistance in nNOS null 
mice was related to a sympathetic mechanism, be-
cause alpha-adrenergic blockade normalised in-
sulin sensitivity in the nNOS null mice, whereas it 
had no detectable effect in the control mice. 
These findings indicate that NOS isoforms regu-
late glucose homeostasis by different mechanisms. 
The insulin resistance of the nNOS null mice 
in the present studies was of similar magnitude to 
the level reported by Shankar and colleagues [16]. 
In eNOS null mice, insulin resistance is related, at 
least in part, to an intrinsic defect of skeletal mus-
cle glucose uptake [11]. This mechanism does not 
appear to contribute to insulin resistance in 
nNOS null mice, because basal and insulin stimu-
lated skeletal muscle glucose uptake in vitro were 
comparable in nNOS null and control mice. This 
surprising finding suggests that NO generated by 
nNOS, which is abundantly expressed in skeletal 
muscle tissue [17], does not appear to be essential 
for maintaining normal glucose homeostasis in 
this tissue. Impaired insulin stimulation of blood 
flow and substrate delivery to skeletal muscle tis-
sue, which are NO-dependent [18], are additional 
mechanisms contributing to insulin resistance in 
eNOS null mice [11]. In the present study, we 
found that insulin stimulation of skeletal muscle 
blood flow during the clamp studies was compa-
rable in the two groups, suggesting that vascular 
function is preserved in nNOS null mice. Consis-
tent with this hypothesis, arterial blood pressure 
was also comparable in the two groups. 
nNOS-derived NO inhibits central sympa-
thetic outflow and counteracts sympathetic vaso-
constriction in skeletal muscle tissue [20, 21, 23], 
and sympathetic overactivity is associated with in-
sulin resistance in animals and humans [7, 27]. To 
test for the involvement of adrenergic mecha-
nisms in the insulin resistance of nNOS null mice, 
we examined the effects of phentolamine on in-
sulin stimulated whole body glucose uptake in the 
SWISS MED WKLY 2007;137:700-704 · www.smw.ch 703 
mg/kg/min), whereas it had no detectable effect 
on the glucose infusion rate in the control mice 
(101 (12) vs 101 (13) [-13 to 12] mg/kg/min) 
(figure 1). After phentolamine, the glucose infu-
sion rates were comparable in the nNOS null and 
control mice (102 (14) vs 101 (12) [-8 to 11] 
mg/kg/min). 
two groups of mice. We found that alpha-adren-
ergic blockade normalised insulin sensitivity in 
the nNOS null mice, whereas it had no detectable 
effect in the control mice. This finding suggests 
that sympathetic overactivity, possibly related to 
the loss of central neural inhibition of sympa-
thetic outflow by nNOS-derived NO, contributes 
to insulin resistance in nNOS null mice. In line 
with this hypothesis, intracerebroventricular in-
jection of L-NMMA in rats causes insulin resist-
ance by a central neural action [21]. 
Taken together with earlier observations, the 
prescnt findings indicate that, in mice, defective 
NO synthesis causes insulin resistance by differ-
ent mechanisms, depending on the NOS iso-
enzyme involved. Whereas in eNOS null mice, 
insulin resistance is related to defects in insulin 
stimulation of muscle perfusion and insulin sig-
nalling in the skeletal muscle cell [11], in nNOS 
null mice these mechanisms do not appear to play 
an important role, and sympathetic mechanisms 
appear to be the main culprit. Insulin resistant 
states in humans are associated with defective NO 
synthesis and/or impaired NO bioavailability, and 
with sympathetic over-activity [7, 9]. Moreover, 
a-adrenergic blockade has been shown to im-
prove insulin sensitivity in insulin resistant sub-
jects [28]. We speculate that loss of central neural 
inhibition of sympathetic outflow by NO may 
also represent a mechanism contributing to in-
sulin resistance and its associated cardiovascular 
complications in humans. 
We are indebted to Dr. Lorenz Hirt for letting us 
use his blood flow measurement equipment, to Mrs. 
Maria-Alba Guardia for technical help with some in vitro 
studies, and to Dr. Philippe Frascarolo for assistance with 
the statistical analysis. 
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